Trademark Overview
On Monday, June 30, 2025, a trademark application was filed for NANOEX with the United States Patent and Trademark Office. The USPTO has given the NANOEX trademark a serial number of 99259207. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Monday, June 30, 2025. This trademark is owned by Kaigene, Inc.. The NANOEX trademark is filed in the Chemical Products and Pharmaceutical Products categories with the following description:
Pharmaceutical and therapeutic preparations, namely, a drug formulation using protein degradation for use in treating immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Biochemical preparations for medical use for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Pharmaceutical preparations for targeted protein degradation, comprising small molecules, peptides, biologics, antibodies designed for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Proteins, protein fragments, and protein conjugates all for use in the manufacture of pharmaceutical preparations for treatment of immunologic diseases, particularly autoimmune diseases
Chemical preparations for scientific purposes; Molecules for use in industry, namely, protein-modulating molecules for use in the pharmaceutical industry; Molecules for use in science, namely, protein-modulating molecules for use in the pharmaceutical industry; Molecules for molecular biology, other than for medical or veterinary use, namely, protein-modulating molecules for use in the pharmaceutical industry